A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy

BACKGROUND: Safe, effective and convenient antiemetic regimens that preserve benefit over repeated cycles are needed for optimal supportive care during cancer treatment. NEPA, an oral fixed-dose combination of netupitant, a highly selective NK(1) receptor antagonist (RA), and palonosetron (PALO), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gralla, R. J., Bosnjak, S. M., Hontsa, A., Balser, C., Rizzi, G., Rossi, G., Borroni, M. E., Jordan, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071753/
https://www.ncbi.nlm.nih.gov/pubmed/24631949
http://dx.doi.org/10.1093/annonc/mdu096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4071753/
https://www.ncbi.nlm.nih.gov/pubmed/24631949
http://dx.doi.org/10.1093/annonc/mdu096

Ejemplares similares